AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen’s high-affinity anti-TIGIT antibody was licensed in 2018 to AstraZeneca for exclusive use in bi-specific and multi-specific antibody products, excluding PVRIG- and/or PVRL2- TIGIT-bispecific products
Moscow’s ‘Massive Strategic Blunder?’ Times Report Says Finland, Sweden Look Set To Join NATO In Summer
Amid a raging war between Russia and Ukraine, two European nations Finland and Sweden look poised to join NATO (North Atlantic Treaty Organisation) this year, as a result of Moscow's “massive strategic blunder,” according to T
